Reuters reports Lilly stock climbed to a new peak Thursday as its blockbuster weight loss shots kept driving sales.
Recap by typeshit. Post by Reuters Legal on X.
The 52-year-old actor points to his early 4am workouts and discipline instead of weight loss shots. A celebrity opinion, not new data.
Metz says the drug improved her mobility enough to handle eight Broadway shows a week in "& Juliet". Her account, not a clinical claim.
A general piece on how GLP-1 drugs like Ozempic and Wegovy reshaped weight management in the US. Light on new details.
The broker says Laurus beat 2QFY27 estimates on EBITDA and profit, with its CDMO pipeline and peptide work driving the higher forecasts.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
A short teaser points to another reported side effect of GLP-1 drugs but doesn't say what it is.
Loading…